Est. 2015 · United Kingdom · USA · Austria
MPN-MDS-26
8th AnnualInvitation Only

MPN-MDS

USFocus Meeting 2027
Two days, 62 people, one room.
April 9 to 10, 2027
Nashville, TN
Support Opportunities →
Dates
April 9-10, 2027
Two-day program
Venue
Nashville, TN
Hotel TBC
Audience
62 by invitation
31 KOLs & 31 fellows
Format
9 sessions · 32 talks
Keynotes, panels + debates

A Curated Room: The People Shaping Practice

This 8th annual, invitation-only meeting convenes a deliberately small faculty: 31 leading MPN and MDS KOLs alongside 31 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.

The science tracks where treatment is moving: mutant CALR and next-generation JAK2 targeting, new options in PV, rational frontline combinations in MF, and molecularly defined MDS from TP53 to IDH. Sessions pair expert talks with a moderated panel, and each day opens with a keynote and a Rising Stars debate, sustained, close-quarters engagement rather than a lecture hall.

Mutant CALR TargetingNovel MF CombinationsRopeg & Rusfertide in PVLR-MDS & EMAsHR-MDS · TP53 · IDHMPN · MDS · MDS/MPN
Meeting Co-Chairs
Listed alphabetically by surname
Prithviraj Bose
Prithviraj Bose
MD Anderson Cancer Center, Houston, TX
Rami Komrokji
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Faculty Drawn From
MD Anderson · Moffitt · Memorial Sloan Kettering · Johns Hopkins · Yale · Fred Hutch and other leading US cancer centers
62
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
21
Established meetings across the US and Europe, a proven platform
MPN-MDS US Focus Meeting 2027

Confirmed Faculty

Listed alphabetically by surname
Hussein Abbas
MD Anderson Cancer Center, Houston, TX
Uma Borate
The Ohio State University Comprehensive Cancer Center, Columbus, OH
Prithviraj Bose
MD Anderson Cancer Center, Houston, TX
Naval Daver
MD Anderson Cancer Center, Houston, TX
Amy Dezern
Johns Hopkins Medicine, Baltimore, MD
Andrew Dunbar
MD Anderson Cancer Center, Houston, TX
Guillermo Garcia Manero
MD Anderson Cancer Center, Houston, TX
Anthony Hunter
Winship Cancer Institute, Emory University, Atlanta, GA
Eli Jabbour
MD Anderson Cancer Center, Houston, TX
Tapan Kadia
MD Anderson Cancer Center, Houston, TX
Hagop Kantarjian
MD Anderson Cancer Center, Houston, TX
Rami Komrokji
Moffitt Cancer Center, Tampa, FL
Andrew Kuykendall
Moffitt Cancer Center, Tampa, FL
Sanam Loghavi
MD Anderson Cancer Center, Houston, TX
Yazan Madanat
UT Southwestern Medical Center, Dallas, TX
Lucia Masarova
MD Anderson Cancer Center, Houston, TX
Ruben Mesa
Atrium Health, Charlotte, NC
Alain Mina
Yale School of Medicine, New Haven, CT
Stephen Oh
Washington University School of Medicine, St. Louis, MO
Naveen Pemmaraju
MD Anderson Cancer Center, Houston, TX
Nikolai Podoltsev
Yale School of Medicine, New Haven, CT
Uday Popat
MD Anderson Cancer Center, Houston, TX
Raajit Rampal
Memorial Sloan Kettering Cancer Center, New York, NY
Lindsay Rein
Duke Cancer Institute, Durham, NC
David Sallman
Moffitt Cancer Center, Tampa, FL
Michael Savona
Vanderbilt University Medical Center, Nashville, TN
Bart Scott
Fred Hutchinson Cancer Center, Seattle, WA
Zhuoer Xie
Moffitt Cancer Center, Tampa, FL
Abdulraheem Yacoub
University of Kansas Medical Center, Kansas City, KS
Amer Zeidan
Yale School of Medicine, New Haven, CT
Further faculty to be announced
Two Days, Nine Sessions

Proposed Agenda

Presentations15 min
Panel Discussions30 min
Lunch Break & Networking50 min
Day One · Friday, April 9, 2027
Keynote Lecture 1: The Future of MPN Management
Ruben MesaAtrium Health, Charlotte, NC
Rising Stars Debate 1: MPN
2 fellows / junior faculty debate
Session ISetting the Stage
Moderator
Myeloid Neoplasms Classification from the Microscope to Clinic
Sanam LoghaviMD Anderson Cancer Center, Houston, TX
The Chicken and the Egg: Clonal Hematopoiesis and Inflammation in MDS
Zhuoer XieMoffitt Cancer Center, Tampa, FL
Rethinking JAK2 Inhibition in MPNs: What's New in Type II and Mutant-Selective Approaches?
Andrew DunbarMD Anderson Cancer Center, Houston, TX
Session IIPV
Moderator
Revisiting Risk Stratification in PV – Isn’t It About Time?
Andrew KuykendallMoffitt Cancer Center, Tampa, FL
Ropeg and Rusfertide – Fight or Join Forces?
Naveen PemmarajuMD Anderson Cancer Center, Houston, TX
Rux and Emerging JAK2 Inhibitors for PV
Nikolai PodoltsevYale School of Medicine, New Haven, CT
Session IIIET and CML
Moderator
Inhibiting Mutant CALR: Ushering in a New Era of Molecularly Targeted Therapy in ET
Lucia MasarovaMD Anderson Cancer Center, Houston, TX
Ropeg Now Approved for ET: Review of the Evidence and Implications for the Future
Abdulraheem YacoubUniversity of Kansas Medical Center, Kansas City, KS
CML 2027 Primer
Eli JabbourMD Anderson Cancer Center, Houston, TX
Session IVMyelofibrosis
Moderator
Frontline Rational Combos in MF and the Need for New Endpoints
Prithviraj BoseMD Anderson Cancer Center, Houston, TX
Mutant CALR Antibodies and AJ1-11095: Game Changing Treatments for MF or Too Soon to Tell?
Raajit RampalMemorial Sloan Kettering Cancer Center, New York, NY
Anemia in MF – Still an Unmet Need?
Stephen OhWashington University School of Medicine, St. Louis, MO
Transplant for MF – Still the Only Potential Cure
Uday PopatMD Anderson Cancer Center, Houston, TX
Special Interest in MPN
Management of Accelerated and Blast Phase MPN
Tapan KadiaMD Anderson Cancer Center, Houston, TX
Partnership Opportunities Now Open

Bespoke engagement packages for a closed, invitation-only audience

Request the Prospectus →
Zeynep Aydagül
Your Point of Contact
Zeynep Aydagül
Account Executive, MD Education